TheStreet upgraded shares of Kamada (NASDAQ:KMDA) from a c rating to a b rating in a report issued on Friday.
A number of other research analysts have also recently commented on KMDA. Jefferies Group reissued a buy rating and issued a $7.00 price target on shares of Kamada in a report on Thursday, October 12th. Zacks Investment Research raised Kamada from a sell rating to a hold rating in a report on Wednesday, October 25th. ValuEngine raised Kamada from a sell rating to a hold rating in a report on Friday, January 5th. Chardan Capital started coverage on Kamada in a report on Friday, February 2nd. They issued a buy rating and a $7.00 price target on the stock. Finally, HC Wainwright reissued a buy rating on shares of Kamada in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Kamada currently has a consensus rating of Buy and an average price target of $7.00.
Kamada (NASDAQ:KMDA) opened at $5.00 on Friday. The company has a quick ratio of 2.58, a current ratio of 3.30 and a debt-to-equity ratio of 0.02. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a market capitalization of $201.31, a P/E ratio of 29.41 and a beta of 1.14.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.10. Kamada had a return on equity of 9.06% and a net margin of 6.71%. The company had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. analysts anticipate that Kamada will post 0.21 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Paulson & CO. Inc. raised its holdings in shares of Kamada by 8.2% during the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after acquiring an additional 60,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares in the last quarter. Analyst IMS Investment Management Services Ltd. raised its holdings in shares of Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares in the last quarter. ARK Investment Management LLC purchased a new stake in shares of Kamada during the 4th quarter worth approximately $251,000. Finally, Worth Venture Partners LLC purchased a new stake in shares of Kamada during the 3rd quarter worth approximately $246,000. 6.26% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/kamada-kmda-upgraded-by-thestreet-to-b.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.